Eventually, PTEN loss leads to dysregulation of EV biogenesis and cargo loading, favoring oncogenic signaling, immune escape, and metastatic behavior; therefore, we assume that EVs can be considered promising biomarkers, offering valuable insights into tumor behavior and opening new avenues for therapeutic strategies, such as targeting EV biogenesis pathways, as a potential approach to cancer treatment. The gene discussed is PTEN; the disease is neoplasm.